Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 29, 2015- First New Drug Application for a GLP-1 receptor agonist to include CV outcomes data -
-
Sep 14, 2015- LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone -
- Aug 31, 2015- Will work together on new digital technology and tools for diabetes -
-
Jul 24, 2015- Praluent available early next week to U.S. patients -
-
Jun 8, 2015- ELIXA is the first event-driven cardiovascular outcomes study to provide data for a GLP-1 receptor agonist -
-
May 21, 2015- Includes study in patients who were inadequate responders to, or intolerant of, TNF-alpha inhibitors -
-
Mar 19, 2015- Results support resubmission of U.S. New Drug Application in Q3 2015 -
- Jan 20, 2015Further education about hypoglycemia and routinely monitoring blood glucose levels is needed
-
Jan 9, 2015- Primary efficacy endpoints met in two trials of alirocumab administered every four weeks -
-
Jan 6, 2015Awards will provide funding for innovative diabetes researchers
